Doctronic Secures $40M Series B to Scale Healthcare Platform

Key Takeaways

1. $40 million Series B co-led by Abstract and Lightspeed Venture Partners brings Doctronic’s total funding to $65 million across three rounds in under 12 months
2. The platform has grown 15x to 8-figure annualized revenue since closing its Series A just six months ago, while nearly tripling its repeat patient rate
3. Doctronic is the first AI system legally authorized to practice medicine in the United States, after becoming the first AI-native platform to autonomously renew prescriptions under Utah’s regulatory sandbox in December 2025
4. The company now sees 300,000+ unique weekly visitors and plans to use fresh capital to expand into pediatrics, new health system partnerships, and multi-state prescription regulatory approvals

Quick Recap

New York-based AI doctor startup Doctronic has officially closed a $40 million Series B funding round, the company announced via Business Wire on March 24, 2026. The round was co-led by Abstract and Lightspeed Venture Partners, with continued participation from existing backers including Union Square Ventures, Seven Stars, Tusk Ventures, and Mantis. This third financing round in under a year lifts Doctronic’s total capital raised to more than $65 million, placing it among the fastest-funded AI health startups in recent memory.

Inside the Numbers of This Deal

Founded in 2023 by Dr. Adam Oskowitz and Matt Pavelle, Doctronic operates a HIPAA-compliant, AI-powered clinical platform that enables patients to receive medical guidance 24/7 at no upfront cost. Users describe their symptoms through a conversational chat interface; the platform generates up to four potential diagnoses, assigns probability estimates, and produces downloadable SOAP notes that patients can share directly with clinicians. When a case requires medication, lab work, or a physician’s judgment, users are transferred to board-certified doctors via video consultation within approximately 15 minutes, for a flat fee of $39 or a standard insurance copay.

The financial trajectory behind this round is what sets Doctronic apart from the typical early-stage health tech story. Since closing its $20 million Series A in September 2025, the company reported 15x revenue growth to 8-figure annualized revenue and nearly tripled its repeat patient rate – metrics rarely seen in the consumer health space at this stage. The platform now serves over 300,000 unique weekly visitors and has conducted more than 15 million medical conversations with over 1 million users – numbers that signal genuine product-market fit, not merely funded growth.

The fresh $40 million will be deployed across three strategic fronts: accelerated hiring, expansion into pediatric services, and forging new co-branded partnerships with digital health companies, payers, and hospital systems. Co-CEO Matt Pavelle has positioned Doctronic as the “digital front door” of healthcare, routing patients efficiently and offering unlimited primary care at a predictable cost. Lightspeed Venture Partners, which led the Series A, doubled down on the investment – a strong signal of institutional conviction.

Regulatory Watershed That Made This Round Possible

The funding does not exist in a vacuum. In December 2025, Doctronic crossed a threshold no AI company had crossed before in American healthcare: it became the first AI-native platform to autonomously renew prescriptions under Utah’s AI Learning Lab regulatory sandbox. The program, a formal agreement between Doctronic and Utah’s Department of Commerce Office of Artificial Intelligence Policy, allows patients with chronic conditions to renew medications through the AI system without requiring direct physician approval, subject to rigorous monthly reporting and clinical safety oversight.

Utah’s AI Learning Lab, created in 2024, functions as a supervised testing environment where professional licensure and scope-of-practice laws can be temporarily waived to evaluate emerging technology in real clinical settings. The Doctronic pilot tracks refill timeliness, patient access, safety outcomes, and adverse events in real time. Regulators in Arizona, Texas, and Wyoming have since begun exploring comparable sandbox frameworks, reflecting a national shift toward evidence-based AI regulation rather than preemptive restriction.

This is also happening against a federal legislative backdrop. The “Healthy Technology Act of 2025”, sponsored by Representative David Schweikert of Arizona, proposes to formally recognize AI as a “practitioner licensed by law to administer such drugs” — a move that, if enacted, would fundamentally rewrite the regulatory map for companies like Doctronic. The bill has been referred to the Committee on Energy and Commerce, and while its passage is not assured, its very existence reflects how seriously Washington is beginning to engage with AI’s role in clinical care.

Competitive Landscape

In identifying the most relevant competitors at Doctronic’s current scale and clinical positioning, two names stand out: K Health and Hippocratic AI. Both operate in the AI-driven patient-facing healthcare space, have received significant institutional funding, and are building toward autonomous or semi-autonomous clinical capabilities – though their models differ materially from Doctronic’s.

Strategic Analysis

Doctronic leads the competitive field in one genuinely unique dimension: regulatory authorization. No competitor has legally crossed the threshold of autonomous AI prescribing in the US, and that first-mover advantage in the regulatory sandbox model is likely to compound as more states open similar programs. K Health holds a significant scale advantage in raw user numbers and institutional partnerships – its integration with the Mayo Clinic Platform gives it a clinical credibility halo that Doctronic is still building toward.

Hippocratic AI, meanwhile, occupies a different lane entirely: with $404 million raised and a $3.5 billion valuation, it has deliberately avoided diagnostic and prescribing use cases to reduce regulatory and liability risk, making it more of a healthcare operations player than a direct Doctronic rival. The core competition between Doctronic and K Health will likely play out on the question of who can move faster from consumer traction to enterprise contracts with health systems and payers — an area where both companies are investing heavily.

Bayelsa Watch’s Takeaway

I’ll be direct: I think this round is a bigger deal than the headline number suggests. Forty million dollars is not a staggering sum in today’s AI funding landscape – we have seen single rounds ten times this size for companies with far fewer real-world proof points. What makes the Doctronic story genuinely compelling is the density of validation packed into under 12 months. A 15x revenue jump, three funding rounds, 300,000 weekly users, and an actual regulatory authorization to practice medicine, all before the company is three years old. In my experience tracking health tech funding cycles, that combination of clinical, regulatory, and commercial momentum hitting simultaneously is rare.

I am also watching the Utah prescription sandbox story very carefully, because I think most people are underestimating its downstream significance. The argument is simple: once a state regulator has formally evaluated an AI system’s clinical safety, published the outcomes, and expanded the program, it becomes the reference case for every other state regulator making the same decision. Doctronic confirmed it is already in discussions with other states to replicate the model. If two or three more states sign on in 2026, the competitive moat deepens considerably, and this becomes a story about regulatory infrastructure, not just a consumer health app.